To observe the effect of Xuezhikang on cardiac function in patients with coronary disease after percutaneous coronary intervention,and to observe the effect of Xuezhikang on blood lipid and plasma FIB level.Methods:Collect 80 patients with coronary disease after percutaneous coronary intervention in our hospital from 2015 to 2016 were randomly selected.The patients were divided into control group and observation group,40 cases in each group.Two groups of patients were treated with basic treatment,the control group was given atorvastatin calcium treatment,the treatment group in the control group on the basis of taking Xuezhikang treatment,were treated for 4 weeks.The levels of blood lipid,plasma Fib,PAI-1 and t-PA were detected before and after treatment,and the cardiac function was evaluated before and after treatment and 3 months after the treatment.Results:After treatment,two patients;1)TG,TCHO,HDL-C and LDL-C were lower than those before treatment(P<0.05),the degree of improvement and the index of the treatment group was significantly better than the control group(P<0.05);2)two groups of plasma Fib and PAI-1 after treatment were decreased,t-PA value increased(P<0.05),and the treatment group was significantly better than the control group(P<0.05);3)the two groups after treatment in patients with heart function were improved,the treatment group than the control group(P<0.05),and 3 months after the indicators were better than the control group(P<0.05).Conclusion:Xuezhikang can reduce blood lipid level of hyperlipidemia patients with coronary disease,improve the blood coagulation,and can significantly improve the prognosis of cardiac function level.